Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (GUIDE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04918810 |
|
Recruitment Status :
Recruiting
First Posted : June 9, 2021
Last Update Posted : March 29, 2023
|
Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborator:
Peter MacCallum Cancer Centre, Australia
Information provided by (Responsible Party):
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 30, 2024 |
| Estimated Study Completion Date : | June 30, 2026 |